Clinical Trials | December 09, 2025
Pharvaris’ deucrictibant shows rapid relief for hereditary angioedema in pivotal Phase 3 trial
The study met its primary endpoint and all 11 secondary efficacy endpoints
The study met its primary endpoint and all 11 secondary efficacy endpoints
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
HYMPAVZI’s safety profile was generally favorable
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Acromegaly, a rare chronic endocrine disorder caused by excess growth hormone, is seeing promising advances in treatment development
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Subscribe To Our Newsletter & Stay Updated
